TORONTO, Canada, June 6/PRNewswire/ -- Archimed, the woundcare division of Insense Ltd., today announced it has received approval from Health Canada for the use of its revolutionary Oxyzyme product in the treatment of difficult and chronic wounds. Oxyzyme was first trialed in Toronto by Dr. Gary Sibbald, one of the world's leading wound care specialists, in 2004 by his team at the Toronto Wound Healing Centres. The announcement was made at the 3rd Congress of the World Union of Wound Healing Societies taking place from June 4-8, 2008 at the Metro Toronto Convention Center.
Oxyzyme is a biochemical system in a dressing that ensures the oxygen in the wound environment meets the diverse oxygen needs of the cells responsible for healing. Ongoing clinical programs being undertaken in Europe are showing that 20% of old, previously unhealable wounds (3.5 years ) are now closing in six weeks or under when dressed with Oxyzyme. Easy to use by any clinical professional, Oxyzyme will now soon be available to the Canadian health care system at a modest cost.
In conjunction with the announcement, Professor T.K. Hunt, often cited as the father of modern wound care, was awarded a lifetime achievement award by the World Union of Wound Healing Societies. Professor Hunt's insight and discoveries on the role oxygen plays in the healing process was the inspiration behind the development of Oxyzyme.
"The real value of Oxyzyme is that it combines two agents - iodine and oxygen - that are essential to the process of wound healing and provides further opportunities to overcome barriers to healing that may exist in the patient," explained Dr. Keith Harding, leading figure in the international wound care community and also a member of the World Union faculty.
For more information about Oxyzyme and Archimed visit http://www.archimed.co.uk.
About Insense Ltd.
------------------
Insense is a British biotechnology company founded by Professor Paul Davis, Chief Scientific Officer, who led the team which invented and developed the ClearBlue(TM) pregnancy test. The company is also developing products out of its core technology for dermatology and health and beauty applications. For more information about Insense Ltd. visit www.insense.co.uk.
For further information: Professor Paul Davis, Chief Scientific Officer , Founder, and Inventor, Paul.davis@insense.co.uk, +44-7825-983-216/
Source: Insense Ltd.
For further information: Professor Paul Davis, Chief Scientific Officer, Founder, and Inventor, Paul.davis@insense.co.uk, +44-7825-983-216/
Sunday, June 8, 2008
Bipolar Disorder: Epidemic Without a Disease
Fred A. Baughman Jr., MD, Neurologist, Child Neurologist*
SAN DIEGO, June 6 /PRNewswire/ -- The following was issued today by Fred A. Baughman Jr., MD:
In the Newsweek cover story of May 26, 2008, Growing Up Bipolar, Mary Carmichael describes yet another magical psychiatric epidemic. In any report of an epidemic there should be a description of the disease of which the epidemic is comprised and mention of the test by which the disease is diagnosed. But nowhere is there mention of a physical abnormality-gross (visible to the naked eye), microscopic or chemical, to make it a disease. Where is the proof that Max Blake, now ten, is other than physically, medically normal?
Symptoms abound. Max can't sleep. Max is sad. Max wants to kill himself. All serious symptoms to be sure, but entirely subjective -- not objective "signs," abnormalities, diseases. Undaunted, Carmichael calls "bipolar" an "elusive disease" with a grave prognosis: a "horror story," in which "terrible things happen." But still no disease.
Next, we are told: "some doctors do not believe (bipolar) exists in children." But diagnosis is not a matter of belief. If no abnormality is demonstrated the diagnosis is "no evidence of disease" -- NED, or "no organic disease" -- NOD.
Absent abnormalities, Carmichael marshals more symptoms: "These babies are born screaming."
Seeking to overwhelm with epidemiology, Carmichael writes: "800,000 children in the United States have been diagnosed." "The disease is hard to pin down." Nor does repeating the word "disease" make it so.
Parents are asked to chose from among the "many drugs" available even though "it's unclear how they work." How could it be otherwise without a disease to treat. No infection, cancer, or diabetes -- all diagnosable, all treatable. In psychiatry, drugs change emotions and behaviors by damaging the normal brain, causing intoxication, poisoning, abnormality -- disease.
"The disease is hard to pin down." "Its unclear how they (the drugs) work." This is not medical science, it is the "medical-speak" of "biological," psychiatry that is deceptive, fraudulent, and intent on peddling drugs. When the patient is known to be normal but is called "diseased" and is "medicated," is that not poisoning? Is it not assault and battery? If the same patient dies, what is that called?
While false diagnostic labels alone may not make persons psychiatric patients-in-perpetuity, drugs which cause chemical dependency and conspicuous injury, such as Parkinson's syndrome or tardive dyskinesia in a seven year-old, surely do. Max's parents were told (1) "treat (your) child and risk a bad outcome," or (2) "don't treat and risk a worse one." In either case, this message is surely to the liking of the pharmaceutical industry which bankrolls it all.
Max and his parents have come to believe the "bipolar" fiction and to play out their roles in it. The main authors -- perpetrators of this and all of psychiatry's fictitious "diseases" are the DSM Committee of the American Psychiatric Association and "researchers" at the National Institute of Mental Health (NIMH).
For Max's mother: "There was one good thing about this strange diagnosis, she thought: at least it meant she wasn't a bad mother." Max and his parents all had roles to play. Max's role is to be "bipolar," a psychiatric patient-in-perpetuity. Everything else would take care of itself and psychiatry and Big Pharma would reap billions a year. And who knows, perhaps the 800,000 "bipolar" Max's Carmichael says we have this year will become 1.5 to 2 million next year, which many think it already is.
Harvard psychiatrists Joseph Biederman and Janet Wozniac were said to have "described" pediatric bipolar disorder in 1995. I have no doubt that they "described" it but, as is the case with all of psychiatry's "chemical imbalances" they have never proved that a single one is an actual disease, as throughout the rest of medicine.
At 2 1/2 years of age, Rebecca Riley of Hull, Massachusetts was "diagnosed" ADHD and bipolar disorder, by child psychiatrist, Dr. Kayoko Kifuji, and was put on Clonidine, Depakote and Seroquel, the last of which is a potent, poisonous, antipsychotic. None had been approved by the FDA for children so young. Rebecca became like a "floppy doll" and died December 13, 2006, at 4 years of age, not from a psychiatric disease, because there is no such thing, but from the very real, very toxic psychiatric drugs prescribed for her. Incredibly, her parents sit in jail, charged with her murder. Who made it appear that Rebecca had two "diseases"? Who convinced the parents she did and that the medications prescribed were "treatments" for them? Countless hundreds if not thousands of children thus diagnosed and drugged are dying, not from psychiatric diseases, but from the one or several drugs prescribed for them as "treatment." Between 1990 and 2000, 186 deaths from methylphenidate-Ritalin were reported to the FDA-MedWatch program, a voluntary reporting program of the FDA itself, says detects no more than 1-10 percent of the actual number.
Who is responsible for the murder of Rebecca Riley? Who is responsible for the thousands or tens of thousands of deaths from prescribed psychiatric drugs for psychiatric "diseases" that do not exist?
* Fred A. Baughman Jr., MD, has discovered and described real diseases and
accepts full responsibility for all opinions and representations herein.
He is a Fellow of the American Academy of Neurology, Diplomate of the
American Board of Psychiatry and Neurology, and author of the book: THE
ADHD FRAUD -- How Psychiatry Makes "Patients" of Normal Children
http://www.trafford.com/
Source: Fred A. Baughman Jr., MD
CONTACT: Fred A. Baughman Jr., MD, +1-619-440-8236,
fredbaughmanmd@cox.net
Web site: http://www.trafford.com/
SAN DIEGO, June 6 /PRNewswire/ -- The following was issued today by Fred A. Baughman Jr., MD:
In the Newsweek cover story of May 26, 2008, Growing Up Bipolar, Mary Carmichael describes yet another magical psychiatric epidemic. In any report of an epidemic there should be a description of the disease of which the epidemic is comprised and mention of the test by which the disease is diagnosed. But nowhere is there mention of a physical abnormality-gross (visible to the naked eye), microscopic or chemical, to make it a disease. Where is the proof that Max Blake, now ten, is other than physically, medically normal?
Symptoms abound. Max can't sleep. Max is sad. Max wants to kill himself. All serious symptoms to be sure, but entirely subjective -- not objective "signs," abnormalities, diseases. Undaunted, Carmichael calls "bipolar" an "elusive disease" with a grave prognosis: a "horror story," in which "terrible things happen." But still no disease.
Next, we are told: "some doctors do not believe (bipolar) exists in children." But diagnosis is not a matter of belief. If no abnormality is demonstrated the diagnosis is "no evidence of disease" -- NED, or "no organic disease" -- NOD.
Absent abnormalities, Carmichael marshals more symptoms: "These babies are born screaming."
Seeking to overwhelm with epidemiology, Carmichael writes: "800,000 children in the United States have been diagnosed." "The disease is hard to pin down." Nor does repeating the word "disease" make it so.
Parents are asked to chose from among the "many drugs" available even though "it's unclear how they work." How could it be otherwise without a disease to treat. No infection, cancer, or diabetes -- all diagnosable, all treatable. In psychiatry, drugs change emotions and behaviors by damaging the normal brain, causing intoxication, poisoning, abnormality -- disease.
"The disease is hard to pin down." "Its unclear how they (the drugs) work." This is not medical science, it is the "medical-speak" of "biological," psychiatry that is deceptive, fraudulent, and intent on peddling drugs. When the patient is known to be normal but is called "diseased" and is "medicated," is that not poisoning? Is it not assault and battery? If the same patient dies, what is that called?
While false diagnostic labels alone may not make persons psychiatric patients-in-perpetuity, drugs which cause chemical dependency and conspicuous injury, such as Parkinson's syndrome or tardive dyskinesia in a seven year-old, surely do. Max's parents were told (1) "treat (your) child and risk a bad outcome," or (2) "don't treat and risk a worse one." In either case, this message is surely to the liking of the pharmaceutical industry which bankrolls it all.
Max and his parents have come to believe the "bipolar" fiction and to play out their roles in it. The main authors -- perpetrators of this and all of psychiatry's fictitious "diseases" are the DSM Committee of the American Psychiatric Association and "researchers" at the National Institute of Mental Health (NIMH).
For Max's mother: "There was one good thing about this strange diagnosis, she thought: at least it meant she wasn't a bad mother." Max and his parents all had roles to play. Max's role is to be "bipolar," a psychiatric patient-in-perpetuity. Everything else would take care of itself and psychiatry and Big Pharma would reap billions a year. And who knows, perhaps the 800,000 "bipolar" Max's Carmichael says we have this year will become 1.5 to 2 million next year, which many think it already is.
Harvard psychiatrists Joseph Biederman and Janet Wozniac were said to have "described" pediatric bipolar disorder in 1995. I have no doubt that they "described" it but, as is the case with all of psychiatry's "chemical imbalances" they have never proved that a single one is an actual disease, as throughout the rest of medicine.
At 2 1/2 years of age, Rebecca Riley of Hull, Massachusetts was "diagnosed" ADHD and bipolar disorder, by child psychiatrist, Dr. Kayoko Kifuji, and was put on Clonidine, Depakote and Seroquel, the last of which is a potent, poisonous, antipsychotic. None had been approved by the FDA for children so young. Rebecca became like a "floppy doll" and died December 13, 2006, at 4 years of age, not from a psychiatric disease, because there is no such thing, but from the very real, very toxic psychiatric drugs prescribed for her. Incredibly, her parents sit in jail, charged with her murder. Who made it appear that Rebecca had two "diseases"? Who convinced the parents she did and that the medications prescribed were "treatments" for them? Countless hundreds if not thousands of children thus diagnosed and drugged are dying, not from psychiatric diseases, but from the one or several drugs prescribed for them as "treatment." Between 1990 and 2000, 186 deaths from methylphenidate-Ritalin were reported to the FDA-MedWatch program, a voluntary reporting program of the FDA itself, says detects no more than 1-10 percent of the actual number.
Who is responsible for the murder of Rebecca Riley? Who is responsible for the thousands or tens of thousands of deaths from prescribed psychiatric drugs for psychiatric "diseases" that do not exist?
* Fred A. Baughman Jr., MD, has discovered and described real diseases and
accepts full responsibility for all opinions and representations herein.
He is a Fellow of the American Academy of Neurology, Diplomate of the
American Board of Psychiatry and Neurology, and author of the book: THE
ADHD FRAUD -- How Psychiatry Makes "Patients" of Normal Children
http://www.trafford.com/
Source: Fred A. Baughman Jr., MD
CONTACT: Fred A. Baughman Jr., MD, +1-619-440-8236,
fredbaughmanmd@cox.net
Web site: http://www.trafford.com/
Saturday, June 7, 2008
When Are Antibiotics for Lyme Disease Medically Necessary?
Guidelines downplay antibiotic treatment for longstanding symptoms
PORTLAND, Ore., June 5 /PRNewswire/ -- As good weather brings people outdoors and into the woods, it also exposes them to tick bites that can result in Lyme disease, one of the fastest growing infectious diseases in the United States. A microscopic bacterial organism, Borrelia burgdorferi, carried by the Ixodes tick causes the Lyme infection. Although the incidence of Lyme disease remains low -- about 100,000 cases each year -- that's a big jump over the 16,000 cases the Center for Disease Control (CDC) noted in 1999.
The CDC and Infectious Diseases Society of America (IDSA) have de-emphasized antibiotics in the treatment of Lyme disease.
"The IDSA released guidelines that are more restrictive about using antibiotics in the three stages of Lyme disease," said Dr. Skip Freedman, Executive Medical Director at AllMed Healthcare Management, a leading independent review organization.
According to Freedman, doctors should consider other diagnostic possibilities first. Prior to diagnosing Lyme disease, they must verify that a patient has recently been in a place where the disease is epidemic -- usually the coastal northeast, mid-Atlantic region, Wisconsin, Minnesota or northern California. Then doctors should follow the current CDC and IDSA guidelines for prescribing courses of antibiotic treatment.
During the first stage of the disease, infected patients may develop a bull's-eye rash. In the second stage, they may show multiple skin lesions that coincide with flu-like symptoms, followed by nonspecific muscular, skeletal, arthritic, neuralgic, psychiatric and even cardiac symptoms.
"A diagnosis of Lyme disease should never be made based on initial blood test screening alone," Freedman said. Doctors must run more specific serologic tests, including an enzyme-linked immunoassay and a Western blot test to check if Lyme disease antibodies are present.
Once doctors determine that a patient is in stage one or two of the disease, it can be easily treated with a two- to four-week course of oral antibiotics. Most doctors prescribe doxycycline, (for adults and children over eight years old) or amoxicillin or cefuroxime (for adults and children under eight). Usually -- but not always -- an early course of antibiotic treatment cures the disease. Even with proper treatment, patients who have Lyme disease may develop symptoms consistent with fibromyalgia or chronic fatigue syndrome. An active infection, however, often isn't the source of such symptoms.
Doctors unfamiliar with Lyme disease often misdiagnose it as multiple sclerosis, rheumatoid arthritis, fibromyalgia, chronic fatigue syndrome or other autoimmune and neurological diseases. Misdiagnosis, as well as delayed or inadequate treatment, may lead to the persistent third stage of the disease.
Without early and medically necessary antibiotic treatment, 10 to 15 percent of Lyme disease patients may display arthritic or even neurological complaints. And 80 percent of patients with Lyme disease develop malaise and fatigue similar to chronic fatigue syndrome. They also may display other symptoms unrelated to Lyme disease.
The current recommendations for diagnosis and care require either the bull's-eye rash or positive specific laboratory tests and only recognize false negatives during the early stages of the disease. The recommendations also suggest that post-Lyme disease syndromes don't respond to long-term antibiotic use.
For more information on leading-edge treatments and their medical necessity, check out http://www.allmedmd.com/peerpoints/cuttingedge/cutting_edge_email.htm. To find out more about the services that independent review organizations offer, go to AllMed's Website at http://www.allmedmd.com/.
Source: AllMed Healthcare Management
CONTACT: Martin Middlewood, +1-360-882-1164, martinm@pacifier.com, for
AllMed Healthcare Management
Web site: http://www.allmedmd.com/
PORTLAND, Ore., June 5 /PRNewswire/ -- As good weather brings people outdoors and into the woods, it also exposes them to tick bites that can result in Lyme disease, one of the fastest growing infectious diseases in the United States. A microscopic bacterial organism, Borrelia burgdorferi, carried by the Ixodes tick causes the Lyme infection. Although the incidence of Lyme disease remains low -- about 100,000 cases each year -- that's a big jump over the 16,000 cases the Center for Disease Control (CDC) noted in 1999.
The CDC and Infectious Diseases Society of America (IDSA) have de-emphasized antibiotics in the treatment of Lyme disease.
"The IDSA released guidelines that are more restrictive about using antibiotics in the three stages of Lyme disease," said Dr. Skip Freedman, Executive Medical Director at AllMed Healthcare Management, a leading independent review organization.
According to Freedman, doctors should consider other diagnostic possibilities first. Prior to diagnosing Lyme disease, they must verify that a patient has recently been in a place where the disease is epidemic -- usually the coastal northeast, mid-Atlantic region, Wisconsin, Minnesota or northern California. Then doctors should follow the current CDC and IDSA guidelines for prescribing courses of antibiotic treatment.
During the first stage of the disease, infected patients may develop a bull's-eye rash. In the second stage, they may show multiple skin lesions that coincide with flu-like symptoms, followed by nonspecific muscular, skeletal, arthritic, neuralgic, psychiatric and even cardiac symptoms.
"A diagnosis of Lyme disease should never be made based on initial blood test screening alone," Freedman said. Doctors must run more specific serologic tests, including an enzyme-linked immunoassay and a Western blot test to check if Lyme disease antibodies are present.
Once doctors determine that a patient is in stage one or two of the disease, it can be easily treated with a two- to four-week course of oral antibiotics. Most doctors prescribe doxycycline, (for adults and children over eight years old) or amoxicillin or cefuroxime (for adults and children under eight). Usually -- but not always -- an early course of antibiotic treatment cures the disease. Even with proper treatment, patients who have Lyme disease may develop symptoms consistent with fibromyalgia or chronic fatigue syndrome. An active infection, however, often isn't the source of such symptoms.
Doctors unfamiliar with Lyme disease often misdiagnose it as multiple sclerosis, rheumatoid arthritis, fibromyalgia, chronic fatigue syndrome or other autoimmune and neurological diseases. Misdiagnosis, as well as delayed or inadequate treatment, may lead to the persistent third stage of the disease.
Without early and medically necessary antibiotic treatment, 10 to 15 percent of Lyme disease patients may display arthritic or even neurological complaints. And 80 percent of patients with Lyme disease develop malaise and fatigue similar to chronic fatigue syndrome. They also may display other symptoms unrelated to Lyme disease.
The current recommendations for diagnosis and care require either the bull's-eye rash or positive specific laboratory tests and only recognize false negatives during the early stages of the disease. The recommendations also suggest that post-Lyme disease syndromes don't respond to long-term antibiotic use.
For more information on leading-edge treatments and their medical necessity, check out http://www.allmedmd.com/peerpoints/cuttingedge/cutting_edge_email.htm. To find out more about the services that independent review organizations offer, go to AllMed's Website at http://www.allmedmd.com/.
Source: AllMed Healthcare Management
CONTACT: Martin Middlewood, +1-360-882-1164, martinm@pacifier.com, for
AllMed Healthcare Management
Web site: http://www.allmedmd.com/
Erase Pain in Mere Minutes
NEW YORK, June 5 /PRNewswire/ -- MS -- Constant muscle and joint pain is a problem for millions of people throughout the country. Rheumatoid arthritis, fibromyalgia, lupus, or even past sports activities or work injuries are all contributors to pain.
(Photo: http://www.newscom.com/cgi-bin/prnh/20080605/NYFNSA02 )
To relieve pain, traditional remedies involve strong anti-inflammatory drugs or muscle relaxers -- many of which have scores of side effects that pain sufferers desperate for relief simply must contend with. What's more, the majority of these medications are taken orally, so it can be anywhere from 45 minutes to an hour before pain relief is realized. But treatments using natural ingredients, such as Dr. Janet's Glucosamine Cream, can be equally or more effective than harsh medicines.
Going With Glucosamine
Glucosamine has long been used to ease joint pain and other ailments. Glucosamine is a compound found naturally in the body, made from glucose and the amino acid glutamine. Glucosamine contributes to the production of glycosaminoglycan, a molecule used in the formation and repair of cartilage and other body tissues.
The production of glucosamine slows down as a person ages. Supplementation with glucosamine is widely used for osteoarthritis conditions, helping to improve elasticity and movement in joints, hence reducing swelling, pain and loss of movement. Studies show that glucosamine can also help stimulate new cartilage growth in as little as 30 days.
Transdermal Delivery
Transdermal delivery, or where a medication is applied to the skin for direct relief, is one of the fastest ways to receive relief from pain. Dr. Janet's Glucosamine Cream is made from a special blend of ingredients that allows it to quickly penetrate the skin. That includes Emu oil, which has been used for thousands of years for its pain-relieving abilities that focus on working on the source of pain. The cream offers fast pain relief without a greasy feeling or unwanted odor, usually within 15 minutes.
Dr. Janet's is not one of those hot/cold menthol rubs in the first aid aisle of the pharmacy. It is specially formulated with ingredients that treat the source of pain, not simply cover it up for a few minutes. It is backed by the expertise of Dr. Janet Maccaro, who once experienced chronic pain and fatigue before finding the natural answer and developing this product.
To try Dr. Janet's Glucosamine risk free for 30 days, call 800-301-5123 and mention code VK81.
Tips to Remain Pain-Free
Stop pain before it starts by following these tips from Dr. Janet.
-- Support braces, wrist guards and other products designed to improve
ergonomics may help alleviate pain and prevent further deterioration.
-- Realize that pain can be a symptom of disease or another condition, not
just aging or physical exertion. If any pain seems out of the ordinary,
visit your doctor.
-- Physical activity can help to relieve pain when done in moderation.
Remaining sedentary can cause further stiffness and locking of joints
and muscles.
Therefore, strive to maintain a healthy weight through diet and exercise.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20080605/NYFNSA02
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com
Source: Dr. Janet's Glucosamine Cream
CONTACT: Metro Editorial Services for Dr. Janet's Glucosamine Cream,
+1-800-223-1600
(Photo: http://www.newscom.com/cgi-bin/prnh/20080605/NYFNSA02 )
To relieve pain, traditional remedies involve strong anti-inflammatory drugs or muscle relaxers -- many of which have scores of side effects that pain sufferers desperate for relief simply must contend with. What's more, the majority of these medications are taken orally, so it can be anywhere from 45 minutes to an hour before pain relief is realized. But treatments using natural ingredients, such as Dr. Janet's Glucosamine Cream, can be equally or more effective than harsh medicines.
Going With Glucosamine
Glucosamine has long been used to ease joint pain and other ailments. Glucosamine is a compound found naturally in the body, made from glucose and the amino acid glutamine. Glucosamine contributes to the production of glycosaminoglycan, a molecule used in the formation and repair of cartilage and other body tissues.
The production of glucosamine slows down as a person ages. Supplementation with glucosamine is widely used for osteoarthritis conditions, helping to improve elasticity and movement in joints, hence reducing swelling, pain and loss of movement. Studies show that glucosamine can also help stimulate new cartilage growth in as little as 30 days.
Transdermal Delivery
Transdermal delivery, or where a medication is applied to the skin for direct relief, is one of the fastest ways to receive relief from pain. Dr. Janet's Glucosamine Cream is made from a special blend of ingredients that allows it to quickly penetrate the skin. That includes Emu oil, which has been used for thousands of years for its pain-relieving abilities that focus on working on the source of pain. The cream offers fast pain relief without a greasy feeling or unwanted odor, usually within 15 minutes.
Dr. Janet's is not one of those hot/cold menthol rubs in the first aid aisle of the pharmacy. It is specially formulated with ingredients that treat the source of pain, not simply cover it up for a few minutes. It is backed by the expertise of Dr. Janet Maccaro, who once experienced chronic pain and fatigue before finding the natural answer and developing this product.
To try Dr. Janet's Glucosamine risk free for 30 days, call 800-301-5123 and mention code VK81.
Tips to Remain Pain-Free
Stop pain before it starts by following these tips from Dr. Janet.
-- Support braces, wrist guards and other products designed to improve
ergonomics may help alleviate pain and prevent further deterioration.
-- Realize that pain can be a symptom of disease or another condition, not
just aging or physical exertion. If any pain seems out of the ordinary,
visit your doctor.
-- Physical activity can help to relieve pain when done in moderation.
Remaining sedentary can cause further stiffness and locking of joints
and muscles.
Therefore, strive to maintain a healthy weight through diet and exercise.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20080605/NYFNSA02
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com
Source: Dr. Janet's Glucosamine Cream
CONTACT: Metro Editorial Services for Dr. Janet's Glucosamine Cream,
+1-800-223-1600
Weight Management Solution Helps You Lose or Gain as Much Weight as You Choose
TUCSON, Ariz., June 5 /PRNewswire/ -- You can lose 15 pounds, 150 pounds and more, or even gain weight if you are below your ideal weight according to a new weight management system designed by Michael Dow, a new author.
(Photo: http://www.newscom.com/cgi-bin/prnh/20080605/NYFNSA03 )
Dow says anyone can learn to manage their weight with this diet. It's described in The Pen and Paper Diet and available at http://stores.lulu.com/thepenandpaperdiet.
"The Pen and Paper Diet is based on the known fact that your body requires a certain amount of calories to maintain a certain weight. If a person consumes excess calories, then fat is produced and a person's weight increases," says Dow.
Dow used a combination of information from The National Academy of Sciences, The Centers for Disease Control, and the United States Department of Agriculture (USDA).
The diet has been understood by all different types of people with all types of educational levels ranging from a high school dropout (non-GED) to an MD. "It allows you to eat what you want and lose weight," Dow says.
"You don't have to eat smaller portions, but you will have to consume less calories during another meal. It's an easy eating plan to maintain your ideal weight for the rest of your life," Dow says.
Dow says that the best thing about the diet is that it can be used by everyone, no matter what activity level a person has or their age. "This diet will be great for the many people that are basically required to be sedentary or have low physical activity due to work and family obligations."
A local Physician and certified Nutritionist, Dr. Nathan Conlee, says the book is "an excellent resource for the public to use who want to keep control of their weight. I do commend you on presenting all the information compiled and ease of application for the general public."
"In my opinion, the book reveals the secrets of other successful weight loss programs like Jenny Craig(R), Weight Watchers(R), and Nutrisystem(R)," says Dow. "The difference is that you only have to buy the book for lifelong reference and you are given the tools to control your weight. The book is all about putting weight management skills into your hands."
An expanded edition is intended for health professionals and has calorie requirement calculations for males and females from the ages of 19 to 84. A US Spanish Edition and a generic international English edition (Metric Edition) have also been published.
The Pen and Paper Diet, $14.95 (expanded edition, $39.95) is available at http://stores.lulu.com/thepenandpaperdiet and will be available in bookstores and other online retailers soon.
Go to http://www.thepenandpaperdiet.com/ for more information.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20080605/NYFNSA03
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com
Source: Dow Creative Enterprises, LLC
CONTACT: Michael Dow of Dow Creative Enterprises, LLC, +1-520-861-3394,
mdow@dowcreativeenterprises.com
Web site: http://www.thepenandpaperdiet.com/
http://stores.lulu.com/thepenandpaperdiet
NOTE TO EDITORS: Dow available for interview, review copies and head shot available. Physician endorsement letter available online.
(Photo: http://www.newscom.com/cgi-bin/prnh/20080605/NYFNSA03 )
Dow says anyone can learn to manage their weight with this diet. It's described in The Pen and Paper Diet and available at http://stores.lulu.com/thepenandpaperdiet.
"The Pen and Paper Diet is based on the known fact that your body requires a certain amount of calories to maintain a certain weight. If a person consumes excess calories, then fat is produced and a person's weight increases," says Dow.
Dow used a combination of information from The National Academy of Sciences, The Centers for Disease Control, and the United States Department of Agriculture (USDA).
The diet has been understood by all different types of people with all types of educational levels ranging from a high school dropout (non-GED) to an MD. "It allows you to eat what you want and lose weight," Dow says.
"You don't have to eat smaller portions, but you will have to consume less calories during another meal. It's an easy eating plan to maintain your ideal weight for the rest of your life," Dow says.
Dow says that the best thing about the diet is that it can be used by everyone, no matter what activity level a person has or their age. "This diet will be great for the many people that are basically required to be sedentary or have low physical activity due to work and family obligations."
A local Physician and certified Nutritionist, Dr. Nathan Conlee, says the book is "an excellent resource for the public to use who want to keep control of their weight. I do commend you on presenting all the information compiled and ease of application for the general public."
"In my opinion, the book reveals the secrets of other successful weight loss programs like Jenny Craig(R), Weight Watchers(R), and Nutrisystem(R)," says Dow. "The difference is that you only have to buy the book for lifelong reference and you are given the tools to control your weight. The book is all about putting weight management skills into your hands."
An expanded edition is intended for health professionals and has calorie requirement calculations for males and females from the ages of 19 to 84. A US Spanish Edition and a generic international English edition (Metric Edition) have also been published.
The Pen and Paper Diet, $14.95 (expanded edition, $39.95) is available at http://stores.lulu.com/thepenandpaperdiet and will be available in bookstores and other online retailers soon.
Go to http://www.thepenandpaperdiet.com/ for more information.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20080605/NYFNSA03
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com
Source: Dow Creative Enterprises, LLC
CONTACT: Michael Dow of Dow Creative Enterprises, LLC, +1-520-861-3394,
mdow@dowcreativeenterprises.com
Web site: http://www.thepenandpaperdiet.com/
http://stores.lulu.com/thepenandpaperdiet
NOTE TO EDITORS: Dow available for interview, review copies and head shot available. Physician endorsement letter available online.
Countertop Appliance Splits Tap Water for Five Uses to Enhance Health, Environment
SAN DIEGO, June 5 /PRNewswire/ -- A water ionization and filtration system designed for home and office use provides unlimited quantities of healthy, eco-friendly bottle free waters for drinking, cooking, beauty (skin/hair), cleaning and sanitizing at pennies per gallon.
(Photo: http://www.newscom.com/cgi-bin/prnh/20080605/NYFNSA04 )
Called "The Life Science Water Apparatus," the device makes five different waters at the touch of a button, ionizing them through electrolysis. The most popular personal and commercial models are available at http://www.optimumhealthwater.net/ .
"Unlike other filtration systems, ionization creates natural, mineral-rich, alkaline, anti-oxidant and micro-clustered drinking water, often referred to as 'miracle water' in Japan," according to Denis Alexander, distributor.
These appliances have been sold in Asia since 1974 by Enagic(TM) of Japan, where they are licensed and approved as medical devices by the government. Used in hospitals and clinics, Enagic(TM) systems are the only ones in the industry to have been endorsed by the prestigious Japanese Association of Preventative Medicine for Adult Disease.
Called Kangen Water(TM), this alkaline anti-oxidant water takes its name from the Japanese word kangen, which translates to "return to original," implying its rejuvenating effect on the body.
The Enagic Water(TM) Ionizers create multiple types of restructured tap water with health and environmental benefits including:
-- Kangen Alkaline Water: Studies have found it can strengthen the immune
system, slow the aging process, promote healthy weight loss, support
optimal colon function, enhance sports performance. Can reduce chronic
pain, inflammation, relieve acid reflux, normalize blood pressure,
lower cholesterol, normalize blood sugar and insulin, relieve
allergies.
-- Strong Kangen Water(TM): Strips oil-based herbicides/pesticides from
produce, enhances taste and prolongs shelf life. Emulsifies oil on
contact, degreases countertops and floors, removes stains from
carpet/clothing.
-- Acid or Beauty Water: Excellent natural skin toner/astringent, skin
and hair conditioner. Treats skin conditions such as eczema and
psoriasis. Cleans glass of any kind.
-- Strong Acid Water: Sanitizes, disinfects, kills bacteria such as E.Coli
and Salmonella on foods/countertops, etc. Treats skin conditions, and
a natural mouthwash alternative.
By eliminating plastic water bottles and most toxic chemical household cleaners and their plastic containers, this technology makes an extremely valuable environmental contribution, saves money and creates the world's healthiest waters.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20080605/NYFNSA04
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com
Source: Optimum Health Water
CONTACT: Denis Alexander of Optimum Health Water, +1-858-442-9969,
healthwater@msn.com
Web site: http://www.optimumhealthwater.net/
NOTE TO EDITORS: Alexander available for interview. Demos can be arranged. Photos, DVD's available. View video clips from Japanese Public television at http://www.optimumhealthwater.net .
(Photo: http://www.newscom.com/cgi-bin/prnh/20080605/NYFNSA04 )
Called "The Life Science Water Apparatus," the device makes five different waters at the touch of a button, ionizing them through electrolysis. The most popular personal and commercial models are available at http://www.optimumhealthwater.net/ .
"Unlike other filtration systems, ionization creates natural, mineral-rich, alkaline, anti-oxidant and micro-clustered drinking water, often referred to as 'miracle water' in Japan," according to Denis Alexander, distributor.
These appliances have been sold in Asia since 1974 by Enagic(TM) of Japan, where they are licensed and approved as medical devices by the government. Used in hospitals and clinics, Enagic(TM) systems are the only ones in the industry to have been endorsed by the prestigious Japanese Association of Preventative Medicine for Adult Disease.
Called Kangen Water(TM), this alkaline anti-oxidant water takes its name from the Japanese word kangen, which translates to "return to original," implying its rejuvenating effect on the body.
The Enagic Water(TM) Ionizers create multiple types of restructured tap water with health and environmental benefits including:
-- Kangen Alkaline Water: Studies have found it can strengthen the immune
system, slow the aging process, promote healthy weight loss, support
optimal colon function, enhance sports performance. Can reduce chronic
pain, inflammation, relieve acid reflux, normalize blood pressure,
lower cholesterol, normalize blood sugar and insulin, relieve
allergies.
-- Strong Kangen Water(TM): Strips oil-based herbicides/pesticides from
produce, enhances taste and prolongs shelf life. Emulsifies oil on
contact, degreases countertops and floors, removes stains from
carpet/clothing.
-- Acid or Beauty Water: Excellent natural skin toner/astringent, skin
and hair conditioner. Treats skin conditions such as eczema and
psoriasis. Cleans glass of any kind.
-- Strong Acid Water: Sanitizes, disinfects, kills bacteria such as E.Coli
and Salmonella on foods/countertops, etc. Treats skin conditions, and
a natural mouthwash alternative.
By eliminating plastic water bottles and most toxic chemical household cleaners and their plastic containers, this technology makes an extremely valuable environmental contribution, saves money and creates the world's healthiest waters.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20080605/NYFNSA04
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com
Source: Optimum Health Water
CONTACT: Denis Alexander of Optimum Health Water, +1-858-442-9969,
healthwater@msn.com
Web site: http://www.optimumhealthwater.net/
NOTE TO EDITORS: Alexander available for interview. Demos can be arranged. Photos, DVD's available. View video clips from Japanese Public television at http://www.optimumhealthwater.net .
The Vitamin B12 Craze - Super Nutrient or Super Hype?
Fleming Pharmaceuticals Lays the Debate to Rest
ST. LOUIS, June 5 /PRNewswire/ -- Celebrities, from high-profile athletes to pop stars, have been known to inject it. Food products, including expensive energy drinks and even candy bars, are laced with massive amounts of it. It's vitamin B12 and it is the nutrient fad of the moment.
Fleming Pharmaceuticals found doses of vitamin B12 in some popular products on the market ranged from 40% all the way up to a whopping 5,000% of the U.S. government's recommended daily intake. But do these massive doses really provide an energy boost?
"There is no clinical evidence that large amounts of B12 provide an immediate surge of energy," said Glenn L. Gordon, MD, a noted gastroenterologist and adjunct assistant professor at St. Louis University. Dr. Gordon asserts that the connection these manufacturers make to energy and vitality is more rooted in the common knowledge that vitamin B12 deficiency is associated with fatigue, weakness and mental confusion.
75 Million Americans are B12 Deficient
Though most common in the elderly, vitamin B12 deficiency can also occur in vegetarians, gastric bypass patents, those suffering from Crohn's disease and Celiac disease and people who take acid blockers, like Pepcid or Zantac, on a long-term and regular basis.
Vitamin B12 deficiency is much more serious than a simple bout of low energy. Left untreated, the condition can lead to significant anemia and serious neurological problems such as dementia-like symptoms, mood swings, depression, numbness, balance problems, shooting sensations in the extremities and urinary incontinence.
Only a blood test by a physician can determine whether a patient is vitamin B12 deficient. Treatment options for vitamin B12 deficiency were once limited to oral supplements for those with normal digestive tracts and painful intramuscular injections for patients whose digestive systems cannot absorb B12 through food or oral supplements.
Recently, the availability of nasal sprays have provided a painless option for vitamin B12 deficiency sufferers. One of the newest FDA-approved vitamin B12 nasal sprays is Fleming Pharmaceutical's CaloMist, a convenient once-daily nasal spray that helps patients maintain consistent vitamin B12 levels in the bloodstream.
If you or a loved one exhibits the classic signs of vitamin B12 deficiency -- fatigue, weakness, depression and mental confusion -- see a doctor right away. Chances are, if you don't fall within any of the risk categories and you eat a balanced diet, you're probably already getting all the B12 your body needs.
Source: Fleming Pharmaceuticals
CONTACT: Mike Weiner of Maccabee Group, +1-612-337-0087, for Fleming
Pharmaceuticals
NOTE TO EDITORS: Dr. Glenn L. Gordon is available for interviews Contact: Mike Weiner Maccabee Group for Fleming Pharmaceuticals 612-337-0087
ST. LOUIS, June 5 /PRNewswire/ -- Celebrities, from high-profile athletes to pop stars, have been known to inject it. Food products, including expensive energy drinks and even candy bars, are laced with massive amounts of it. It's vitamin B12 and it is the nutrient fad of the moment.
Fleming Pharmaceuticals found doses of vitamin B12 in some popular products on the market ranged from 40% all the way up to a whopping 5,000% of the U.S. government's recommended daily intake. But do these massive doses really provide an energy boost?
"There is no clinical evidence that large amounts of B12 provide an immediate surge of energy," said Glenn L. Gordon, MD, a noted gastroenterologist and adjunct assistant professor at St. Louis University. Dr. Gordon asserts that the connection these manufacturers make to energy and vitality is more rooted in the common knowledge that vitamin B12 deficiency is associated with fatigue, weakness and mental confusion.
75 Million Americans are B12 Deficient
Though most common in the elderly, vitamin B12 deficiency can also occur in vegetarians, gastric bypass patents, those suffering from Crohn's disease and Celiac disease and people who take acid blockers, like Pepcid or Zantac, on a long-term and regular basis.
Vitamin B12 deficiency is much more serious than a simple bout of low energy. Left untreated, the condition can lead to significant anemia and serious neurological problems such as dementia-like symptoms, mood swings, depression, numbness, balance problems, shooting sensations in the extremities and urinary incontinence.
Only a blood test by a physician can determine whether a patient is vitamin B12 deficient. Treatment options for vitamin B12 deficiency were once limited to oral supplements for those with normal digestive tracts and painful intramuscular injections for patients whose digestive systems cannot absorb B12 through food or oral supplements.
Recently, the availability of nasal sprays have provided a painless option for vitamin B12 deficiency sufferers. One of the newest FDA-approved vitamin B12 nasal sprays is Fleming Pharmaceutical's CaloMist, a convenient once-daily nasal spray that helps patients maintain consistent vitamin B12 levels in the bloodstream.
If you or a loved one exhibits the classic signs of vitamin B12 deficiency -- fatigue, weakness, depression and mental confusion -- see a doctor right away. Chances are, if you don't fall within any of the risk categories and you eat a balanced diet, you're probably already getting all the B12 your body needs.
Source: Fleming Pharmaceuticals
CONTACT: Mike Weiner of Maccabee Group, +1-612-337-0087, for Fleming
Pharmaceuticals
NOTE TO EDITORS: Dr. Glenn L. Gordon is available for interviews Contact: Mike Weiner Maccabee Group for Fleming Pharmaceuticals 612-337-0087
Long Term Care - A Health Qualifying Product
ONTARIO, Calif., June 5 /PRNewswire/ -- Baby boomers and senior boomers are getting bombarded with sales pitches about their futures, their retirement and getting old. Don't let the whirlwind messages and slick marketing put you on the fast track to a bad decision, says Frank N. Darras, the nation's leading disability and long term care insurance lawyer.
(Photo: http://www.newscom.com/cgi-bin/prnh/20070717/NYFNSC02)
"First of all, it is important to take your time and make the very best choice for you and your family," says Darras, who has counseled clients on disability and long term care insurance issues for more than 20 years. See http://www.darrasnews.com/.
Most folks don't start considering Long-Term Care until they are approaching age 60, but a key ingredient in the decision to purchase is your family's health history.
"Many advisors who sell Long-Term Care policies agree that people who have family health histories of cancer, heart attacks and a myriad of other deadly diseases, would be well advised to consider purchasing Long-Term Care at an earlier age. In these circumstances, age is less the determinant than critical health issues," says Darras.
Purchasing coverage to protect you when you get old is very personal and policyholders should consider shopping earlier in life when the premiums are less expensive.
"Do plenty of research, pick your LTC carrier wisely," says Darras. "Understand as we age, our health history may prevent us from qualifying for Long-Term care, so consider your options early on."
Darras advises that it is important to read and understand the language in your policy and know the definition of skilled care, intermediate care and custodial care. Your choice of policies should include those that pay for all three categories including care given by non-professionals, such as family members or friends in the comfort of your own home. Make sure you don't need a written plan of care by your doctor or your carrier before you incur service charges.
To ensure you and your family are protected, get a sound second opinion. Your Long-Term Care decisions should prevent you from outliving your retirement nest egg and becoming a burden to those you love, no matter what your age." says Darras.
For more information see http://www.darrasnews.com/ or call toll free 800-458-4577.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Frank N. Darras https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=39767
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20070717/NYFNSC02
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com
Source: Frank N. Darras
CONTACT: Robin Nolan, +1-650-279-9512, robin@mcdavidpr.com, for Frank N.
Darras
Web site: http://www.darrasnews.com/
(Photo: http://www.newscom.com/cgi-bin/prnh/20070717/NYFNSC02)
"First of all, it is important to take your time and make the very best choice for you and your family," says Darras, who has counseled clients on disability and long term care insurance issues for more than 20 years. See http://www.darrasnews.com/.
Most folks don't start considering Long-Term Care until they are approaching age 60, but a key ingredient in the decision to purchase is your family's health history.
"Many advisors who sell Long-Term Care policies agree that people who have family health histories of cancer, heart attacks and a myriad of other deadly diseases, would be well advised to consider purchasing Long-Term Care at an earlier age. In these circumstances, age is less the determinant than critical health issues," says Darras.
Purchasing coverage to protect you when you get old is very personal and policyholders should consider shopping earlier in life when the premiums are less expensive.
"Do plenty of research, pick your LTC carrier wisely," says Darras. "Understand as we age, our health history may prevent us from qualifying for Long-Term care, so consider your options early on."
Darras advises that it is important to read and understand the language in your policy and know the definition of skilled care, intermediate care and custodial care. Your choice of policies should include those that pay for all three categories including care given by non-professionals, such as family members or friends in the comfort of your own home. Make sure you don't need a written plan of care by your doctor or your carrier before you incur service charges.
To ensure you and your family are protected, get a sound second opinion. Your Long-Term Care decisions should prevent you from outliving your retirement nest egg and becoming a burden to those you love, no matter what your age." says Darras.
For more information see http://www.darrasnews.com/ or call toll free 800-458-4577.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Frank N. Darras https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=39767
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20070717/NYFNSC02
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com
Source: Frank N. Darras
CONTACT: Robin Nolan, +1-650-279-9512, robin@mcdavidpr.com, for Frank N.
Darras
Web site: http://www.darrasnews.com/
TriLipix in Combination with CRESTOR (rosuvastatin calcium) Demonstrates Similar Lipid Effects in Patients with Diabetes and Overall Study Population
Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
TriLipix in Combination with CRESTOR (rosuvastatin calcium) Demonstrates Similar Lipid Effects in Patients with Diabetes and Overall Study Population
SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- New data from a sub-group analysis of patients with mixed dyslipidemia and type 2 diabetes that were enrolled in a Phase III study showed that the use of Abbott's investigational TriLipix(TM) (ABT-335) in combination with AstraZeneca's CRESTOR(R) (rosuvastatin calcium), demonstrated similar improvements in LDL "bad" cholesterol, HDL "good" cholesterol and triglycerides compared to the overall study population. These data were presented today at the American Diabetes Association's (ADA) 68th Annual Scientific Sessions in San Francisco.
Abbott evaluated the efficacy and safety of TriLipix in combination with rosuvastatin in a Phase III study of more than 1,400 patients with mixed dyslipidemia. This study, presented at the National Lipid Association annual meeting on May 31, 2008, met its primary endpoints. TriLipix in combination with rosuvastatin significantly improved HDL and triglycerides compared to rosuvastatin alone, and significantly improved LDL compared to TriLipix alone.
Of the patients enrolled in this study, a sub-group of 276 patients were identified as having type 2 diabetes. Data from this sub-group demonstrated that the comprehensive effect of TriLipix in combination with rosuvastatin was similar to that seen in the overall study population. Compared to corresponding monotherapies, patients receiving TriLipix in combination with rosuvastatin had significant decreases in triglycerides and LDL, in addition to clinically meaningful improvements in HDL.
Dyslipidemia affects millions of Americans living with diabetes. These patients often have mixed dyslipidemia, a complex combination of lipid problems commonly characterized by high triglycerides, low HDL and moderately high LDL.
"Treatment guidelines recommend aggressive treatment of lipids in patients with mixed dyslipidemia and type 2 diabetes," said Peter H. Jones, M.D., FACP, Methodist DeBakey Heart and Vascular Center, Houston, and a lead investigator of the trial. "A comprehensive approach may be necessary to help these patients manage their lipids."
About the Study
This 12-week, multi-center, double blind, controlled Phase III study of 1,400 patients evaluated the efficacy and safety of TriLipix in combination with rosuvastatin on multiple lipid parameters. Patients enrolled in the study had multiple lipid problems, with baseline LDL greater than or equal to 130 mg/dL, HDL less than 40 mg/dL for males and less than 50 mg/dL for females and triglycerides greater than or equal to 150 mg/dL.
Patients were randomized to receive TriLipix (135mg) combined with either 10mg or 20mg of rosuvastatin, TriLipix alone (135mg) or rosuvastatin alone (10mg, 20mg or 40mg). The 40mg rosuvastatin arm was included in the study to assess safety and adverse events, but was not included in the statistical analysis.
The primary comparisons were mean percent change in HDL and triglycerides for TriLipix combined with rosuvastatin compared to rosuvastatin alone, and mean percent change in LDL for TriLipix combined with rosuvastatin compared to TriLipix alone. The combination of TriLipix and rosuvastatin significantly improved LDL compared to TriLipix alone, and significantly improved HDL and triglycerides compared to rosuvastatin alone.
A total of 276 patients included in the primary efficacy analysis had type 2 diabetes and were included in a sub-group analysis. Diabetic patients treated with the combination of TriLipix 135mg and rosuvastatin 10mg had an increase in HDL of 21.0 percent and decrease in triglycerides of 44.7 percent compared to an HDL increase of 6.6 percent and triglyceride decrease of 28.8 percent with rosuvastatin 10mg alone. LDL decreased 37.1 percent with the combination compared to 6.1 percent with TriLipix 135mg monotherapy.
Patients treated with the combination of TriLipix 135mg and rosuvastatin 20mg had an increase in HDL of 17.6 percent and decrease in triglycerides of 42.4 percent compared to an HDL increase of 12.2 percent and triglyceride decrease of 26.8 percent with rosuvastatin 20mg alone. LDL decreased 37.4 percent with the combination compared to 6.1 percent with TriLipix 135mg monotherapy.
"New treatment options are critical given that a substantial number of patients are not achieving treatment goals for their three key lipids," said Eugene Sun, M.D., vice president, Global Pharmaceutical Clinical Development, Abbott. "Abbott has built a robust clinical program to support TriLipix to provide physicians and patients with as much data as possible to help them evaluate this potential new therapy."
About the TriLipix Clinical Trial Program
The efficacy and safety of TriLipix in combination with the three most commonly prescribed statins -- rosuvastatin, atorvastatin and simvastatin -- were evaluated in three randomized, multi-center, double-blind, controlled, 12-week Phase III studies, totaling 2,698 patients with mixed dyslipidemia.
These studies, along with a 52-week long-term safety and efficacy open-label extension study of 1,911 patients, represent the largest program to date examining a fibrate in combination with statins. More than 2,200 patients were treated with TriLipix alone and in combination with statins across these four studies.
The primary data for TriLipix combined with statins were presented at scientific forums earlier this year.
About TriLipix (ABT-335)
TriLipix is an investigational new fenofibric acid molecule, currently in clinical development for treating patients with unhealthy lipid levels, including LDL cholesterol, triglycerides and HDL cholesterol. A New Drug Application (NDA) for TriLipix for use as monotherapy and in combination with statins has been submitted to the U.S. Food and Drug Administration (FDA). Abbott and AstraZeneca are working together to co-develop and market a fixed-dose combination of TriLipix and CRESTOR, for which the companies plan to submit an NDA to the FDA in 2009.
About Abbott
Abbott (NYSE:ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at www.abbott.com.
Source: Abbott
CONTACT: Media: Elizabeth Hoff, +1-847-935-4236, or Financial: Lawrence
Peepo, +1-847-935-6722, both of Abbott
Web site: http://www.abbott.com/
TriLipix in Combination with CRESTOR (rosuvastatin calcium) Demonstrates Similar Lipid Effects in Patients with Diabetes and Overall Study Population
SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- New data from a sub-group analysis of patients with mixed dyslipidemia and type 2 diabetes that were enrolled in a Phase III study showed that the use of Abbott's investigational TriLipix(TM) (ABT-335) in combination with AstraZeneca's CRESTOR(R) (rosuvastatin calcium), demonstrated similar improvements in LDL "bad" cholesterol, HDL "good" cholesterol and triglycerides compared to the overall study population. These data were presented today at the American Diabetes Association's (ADA) 68th Annual Scientific Sessions in San Francisco.
Abbott evaluated the efficacy and safety of TriLipix in combination with rosuvastatin in a Phase III study of more than 1,400 patients with mixed dyslipidemia. This study, presented at the National Lipid Association annual meeting on May 31, 2008, met its primary endpoints. TriLipix in combination with rosuvastatin significantly improved HDL and triglycerides compared to rosuvastatin alone, and significantly improved LDL compared to TriLipix alone.
Of the patients enrolled in this study, a sub-group of 276 patients were identified as having type 2 diabetes. Data from this sub-group demonstrated that the comprehensive effect of TriLipix in combination with rosuvastatin was similar to that seen in the overall study population. Compared to corresponding monotherapies, patients receiving TriLipix in combination with rosuvastatin had significant decreases in triglycerides and LDL, in addition to clinically meaningful improvements in HDL.
Dyslipidemia affects millions of Americans living with diabetes. These patients often have mixed dyslipidemia, a complex combination of lipid problems commonly characterized by high triglycerides, low HDL and moderately high LDL.
"Treatment guidelines recommend aggressive treatment of lipids in patients with mixed dyslipidemia and type 2 diabetes," said Peter H. Jones, M.D., FACP, Methodist DeBakey Heart and Vascular Center, Houston, and a lead investigator of the trial. "A comprehensive approach may be necessary to help these patients manage their lipids."
About the Study
This 12-week, multi-center, double blind, controlled Phase III study of 1,400 patients evaluated the efficacy and safety of TriLipix in combination with rosuvastatin on multiple lipid parameters. Patients enrolled in the study had multiple lipid problems, with baseline LDL greater than or equal to 130 mg/dL, HDL less than 40 mg/dL for males and less than 50 mg/dL for females and triglycerides greater than or equal to 150 mg/dL.
Patients were randomized to receive TriLipix (135mg) combined with either 10mg or 20mg of rosuvastatin, TriLipix alone (135mg) or rosuvastatin alone (10mg, 20mg or 40mg). The 40mg rosuvastatin arm was included in the study to assess safety and adverse events, but was not included in the statistical analysis.
The primary comparisons were mean percent change in HDL and triglycerides for TriLipix combined with rosuvastatin compared to rosuvastatin alone, and mean percent change in LDL for TriLipix combined with rosuvastatin compared to TriLipix alone. The combination of TriLipix and rosuvastatin significantly improved LDL compared to TriLipix alone, and significantly improved HDL and triglycerides compared to rosuvastatin alone.
A total of 276 patients included in the primary efficacy analysis had type 2 diabetes and were included in a sub-group analysis. Diabetic patients treated with the combination of TriLipix 135mg and rosuvastatin 10mg had an increase in HDL of 21.0 percent and decrease in triglycerides of 44.7 percent compared to an HDL increase of 6.6 percent and triglyceride decrease of 28.8 percent with rosuvastatin 10mg alone. LDL decreased 37.1 percent with the combination compared to 6.1 percent with TriLipix 135mg monotherapy.
Patients treated with the combination of TriLipix 135mg and rosuvastatin 20mg had an increase in HDL of 17.6 percent and decrease in triglycerides of 42.4 percent compared to an HDL increase of 12.2 percent and triglyceride decrease of 26.8 percent with rosuvastatin 20mg alone. LDL decreased 37.4 percent with the combination compared to 6.1 percent with TriLipix 135mg monotherapy.
"New treatment options are critical given that a substantial number of patients are not achieving treatment goals for their three key lipids," said Eugene Sun, M.D., vice president, Global Pharmaceutical Clinical Development, Abbott. "Abbott has built a robust clinical program to support TriLipix to provide physicians and patients with as much data as possible to help them evaluate this potential new therapy."
About the TriLipix Clinical Trial Program
The efficacy and safety of TriLipix in combination with the three most commonly prescribed statins -- rosuvastatin, atorvastatin and simvastatin -- were evaluated in three randomized, multi-center, double-blind, controlled, 12-week Phase III studies, totaling 2,698 patients with mixed dyslipidemia.
These studies, along with a 52-week long-term safety and efficacy open-label extension study of 1,911 patients, represent the largest program to date examining a fibrate in combination with statins. More than 2,200 patients were treated with TriLipix alone and in combination with statins across these four studies.
The primary data for TriLipix combined with statins were presented at scientific forums earlier this year.
About TriLipix (ABT-335)
TriLipix is an investigational new fenofibric acid molecule, currently in clinical development for treating patients with unhealthy lipid levels, including LDL cholesterol, triglycerides and HDL cholesterol. A New Drug Application (NDA) for TriLipix for use as monotherapy and in combination with statins has been submitted to the U.S. Food and Drug Administration (FDA). Abbott and AstraZeneca are working together to co-develop and market a fixed-dose combination of TriLipix and CRESTOR, for which the companies plan to submit an NDA to the FDA in 2009.
About Abbott
Abbott (NYSE:ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at www.abbott.com.
Source: Abbott
CONTACT: Media: Elizabeth Hoff, +1-847-935-4236, or Financial: Lawrence
Peepo, +1-847-935-6722, both of Abbott
Web site: http://www.abbott.com/
Monday, April 14, 2008
A Cold Sore Is Often A Warning Sign of Deeper Health Issues, Expert Says
SEATTLE, April 8, 2008 /PRNewswire/ -- The appearance of a cold sore is a sign that your immune system needs a tune-up before other more serious illnesses emerge, according to John Sherman, ND, noted naturopathic physician and former Clinic Director for Bastyr University.
Worldwide, between 80% and 90% of the adult population have the cold sore virus (Herpes Simplex Virus or HSV-1), according to Dr. Sherman, who is the author of The Complete Botanical Prescriber and medical advisor for http://www.surenature.com/.
"Cold sores are more than just a cosmetic issue," says Dr. Sherman. "Our immune systems let us know when it's time to pay attention, and a cold sore is a big red flag."
Prevention is the key. And preventing cold sores through natural, immune-enhancing means has the added advantage of helping to prevent a host of other potential health problems, including influenza, rhinovirus and chronic problems like asthma, irritable bowel syndrome and autoimmune diseases.
"I've been treating cold sore patients for nearly 30 years, and in my experience, 100 percent of the time the appearance of a cold sore is an indication that there is something else going on in the body that needs to be addressed."
Dr. Sherman suggests a few simple tips for maintaining a healthy smile on the outside, while keeping the body healthy on the inside.
-- Get plenty of sleep. When you sleep your body rebuilds its defenses
and reenergizes your immune system.
-- Eat smart. A balanced diet not only makes you feel better, it reduces
the likelihood of outbreaks and lessens their duration.
-- Cut the sugar. Cold sores tend to emerge when your body is too acidic.
Alcohol, soda pop and sweet foods tend to acidify the system and make
cold sores happen more often.
-- Buy organic. Organic foods supply more trace minerals that help
alkalinize your blood, reducing acidity and thereby reducing
outbreaks.
-- Be proactive. Probiotics and targeted, immune-boosting botanicals,
like those in Sure Nature's ImmunaSure (available at
http://www.surenature.com/), have been proven effective in helping with
cold sore symptoms, shortening outbreaks and keeping cold sores from
coming back.
-- Treat from within. Topical creams and lotions may reduce the
appearance and discomfort of cold sores, but they don't prevent them
from reoccurring.
-- Trust your body. The prescription anti-viral cold sore drugs on the
market can have serious side effects on your liver and kidneys and may
actually weaken your body's ability to fight the virus naturally.
"It's important to treat cold sores on a number of different levels," adds Dr. Sherman. "I developed ImmunaSure with natural ingredients shown to have strong anti-viral and anti-inflammatory effects and boost the growth of good bacteria to help maximize immune function -- without the side effects of pharmaceutical treatments."
Contact:
Jennifer Allen Newton
Bluehouse Consulting Group, Inc.
503-805-7540
Jennifer@bluehousecg.com
Source: Sure Nature
CONTACT: Jennifer Allen Newton of Bluehouse Consulting Group, Inc.,
+1-503-805-7540, Jennifer@bluehousecg.com, for Sure Nature
Web site: http://www.surenature.com/
Worldwide, between 80% and 90% of the adult population have the cold sore virus (Herpes Simplex Virus or HSV-1), according to Dr. Sherman, who is the author of The Complete Botanical Prescriber and medical advisor for http://www.surenature.com/.
"Cold sores are more than just a cosmetic issue," says Dr. Sherman. "Our immune systems let us know when it's time to pay attention, and a cold sore is a big red flag."
Prevention is the key. And preventing cold sores through natural, immune-enhancing means has the added advantage of helping to prevent a host of other potential health problems, including influenza, rhinovirus and chronic problems like asthma, irritable bowel syndrome and autoimmune diseases.
"I've been treating cold sore patients for nearly 30 years, and in my experience, 100 percent of the time the appearance of a cold sore is an indication that there is something else going on in the body that needs to be addressed."
Dr. Sherman suggests a few simple tips for maintaining a healthy smile on the outside, while keeping the body healthy on the inside.
-- Get plenty of sleep. When you sleep your body rebuilds its defenses
and reenergizes your immune system.
-- Eat smart. A balanced diet not only makes you feel better, it reduces
the likelihood of outbreaks and lessens their duration.
-- Cut the sugar. Cold sores tend to emerge when your body is too acidic.
Alcohol, soda pop and sweet foods tend to acidify the system and make
cold sores happen more often.
-- Buy organic. Organic foods supply more trace minerals that help
alkalinize your blood, reducing acidity and thereby reducing
outbreaks.
-- Be proactive. Probiotics and targeted, immune-boosting botanicals,
like those in Sure Nature's ImmunaSure (available at
http://www.surenature.com/), have been proven effective in helping with
cold sore symptoms, shortening outbreaks and keeping cold sores from
coming back.
-- Treat from within. Topical creams and lotions may reduce the
appearance and discomfort of cold sores, but they don't prevent them
from reoccurring.
-- Trust your body. The prescription anti-viral cold sore drugs on the
market can have serious side effects on your liver and kidneys and may
actually weaken your body's ability to fight the virus naturally.
"It's important to treat cold sores on a number of different levels," adds Dr. Sherman. "I developed ImmunaSure with natural ingredients shown to have strong anti-viral and anti-inflammatory effects and boost the growth of good bacteria to help maximize immune function -- without the side effects of pharmaceutical treatments."
Contact:
Jennifer Allen Newton
Bluehouse Consulting Group, Inc.
503-805-7540
Jennifer@bluehousecg.com
Source: Sure Nature
CONTACT: Jennifer Allen Newton of Bluehouse Consulting Group, Inc.,
+1-503-805-7540, Jennifer@bluehousecg.com, for Sure Nature
Web site: http://www.surenature.com/
Subscribe to:
Posts (Atom)
blogging